Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells

Kim C. Ohaegbulam, Weifeng Liu, Hyungjun Jeon, Steven C. Almo, Xingxing Zang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

B7x (B7-H4 or B7S1) is a coinhibitory member of the B7 immune checkpoint ligand family that regulates immune function following ligation with its unknown cognate receptors. B7x has limited expression on normal tissues, but is up-regulated on solid human tumors to inhibit anti-tumor immunity and associates with poor clinical prognosis. We assessed the contribution of cytokine stimuli to induce surface B7x expression on cancer cells and the role of tumor-expressed B7x in a murine pulmonary metastasis model, and finally evaluated the potential interaction between B7x and Neuropilin-1, a suggested potential cognate receptor. We showed that proinflammatory and anti-inflammatory cytokines IFNγ, TNFα, and IL-10 did not induce expression of B7x on human or murine cancer cells. Following i.v. injection of CT26, a murine colon cancer cell line in the BALB/c background, we observed a significant increase in tumor burden in the lung of B7x-expressing CT26 mice compared to B7xnegative parental CT26 control mice. This was marked by a significant increase in M2 tumor associated macrophages and antigen-specific CD8 T cell exhaustion. Finally, we found through multiple systems that there was no evidence for B7x and Neuropilin-1 direct interaction. Thus, the B7x pathway has an essential role in modulating the innate and adaptive immune cell infiltrate in the tumor microenvironment with its currently unknown cognate receptor(s).

Original languageEnglish (US)
Pages (from-to)82740-82753
Number of pages14
JournalOncotarget
Volume8
Issue number47
DOIs
StatePublished - 2017

Fingerprint

CD8 Antigens
T-Lymphocytes
Neuropilin-1
Neoplasms
Cytokines
Lung
Tumor Microenvironment
Tumor Burden
Interleukin-10
Colonic Neoplasms
Ligation
Immunity
Anti-Inflammatory Agents
Macrophages
Neoplasm Metastasis
Ligands
Cell Line
Injections

Keywords

  • B7x
  • CD8 T cells
  • Immune checkpoint
  • Innate cells
  • Pulmonary metastases

ASJC Scopus subject areas

  • Oncology

Cite this

Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells. / Ohaegbulam, Kim C.; Liu, Weifeng; Jeon, Hyungjun; Almo, Steven C.; Zang, Xingxing.

In: Oncotarget, Vol. 8, No. 47, 2017, p. 82740-82753.

Research output: Contribution to journalArticle

@article{4a6651aee9744a35b0bf39eb5f53f295,
title = "Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells",
abstract = "B7x (B7-H4 or B7S1) is a coinhibitory member of the B7 immune checkpoint ligand family that regulates immune function following ligation with its unknown cognate receptors. B7x has limited expression on normal tissues, but is up-regulated on solid human tumors to inhibit anti-tumor immunity and associates with poor clinical prognosis. We assessed the contribution of cytokine stimuli to induce surface B7x expression on cancer cells and the role of tumor-expressed B7x in a murine pulmonary metastasis model, and finally evaluated the potential interaction between B7x and Neuropilin-1, a suggested potential cognate receptor. We showed that proinflammatory and anti-inflammatory cytokines IFNγ, TNFα, and IL-10 did not induce expression of B7x on human or murine cancer cells. Following i.v. injection of CT26, a murine colon cancer cell line in the BALB/c background, we observed a significant increase in tumor burden in the lung of B7x-expressing CT26 mice compared to B7xnegative parental CT26 control mice. This was marked by a significant increase in M2 tumor associated macrophages and antigen-specific CD8 T cell exhaustion. Finally, we found through multiple systems that there was no evidence for B7x and Neuropilin-1 direct interaction. Thus, the B7x pathway has an essential role in modulating the innate and adaptive immune cell infiltrate in the tumor microenvironment with its currently unknown cognate receptor(s).",
keywords = "B7x, CD8 T cells, Immune checkpoint, Innate cells, Pulmonary metastases",
author = "Ohaegbulam, {Kim C.} and Weifeng Liu and Hyungjun Jeon and Almo, {Steven C.} and Xingxing Zang",
year = "2017",
doi = "10.18632/oncotarget.21098",
language = "English (US)",
volume = "8",
pages = "82740--82753",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "47",

}

TY - JOUR

T1 - Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells

AU - Ohaegbulam, Kim C.

AU - Liu, Weifeng

AU - Jeon, Hyungjun

AU - Almo, Steven C.

AU - Zang, Xingxing

PY - 2017

Y1 - 2017

N2 - B7x (B7-H4 or B7S1) is a coinhibitory member of the B7 immune checkpoint ligand family that regulates immune function following ligation with its unknown cognate receptors. B7x has limited expression on normal tissues, but is up-regulated on solid human tumors to inhibit anti-tumor immunity and associates with poor clinical prognosis. We assessed the contribution of cytokine stimuli to induce surface B7x expression on cancer cells and the role of tumor-expressed B7x in a murine pulmonary metastasis model, and finally evaluated the potential interaction between B7x and Neuropilin-1, a suggested potential cognate receptor. We showed that proinflammatory and anti-inflammatory cytokines IFNγ, TNFα, and IL-10 did not induce expression of B7x on human or murine cancer cells. Following i.v. injection of CT26, a murine colon cancer cell line in the BALB/c background, we observed a significant increase in tumor burden in the lung of B7x-expressing CT26 mice compared to B7xnegative parental CT26 control mice. This was marked by a significant increase in M2 tumor associated macrophages and antigen-specific CD8 T cell exhaustion. Finally, we found through multiple systems that there was no evidence for B7x and Neuropilin-1 direct interaction. Thus, the B7x pathway has an essential role in modulating the innate and adaptive immune cell infiltrate in the tumor microenvironment with its currently unknown cognate receptor(s).

AB - B7x (B7-H4 or B7S1) is a coinhibitory member of the B7 immune checkpoint ligand family that regulates immune function following ligation with its unknown cognate receptors. B7x has limited expression on normal tissues, but is up-regulated on solid human tumors to inhibit anti-tumor immunity and associates with poor clinical prognosis. We assessed the contribution of cytokine stimuli to induce surface B7x expression on cancer cells and the role of tumor-expressed B7x in a murine pulmonary metastasis model, and finally evaluated the potential interaction between B7x and Neuropilin-1, a suggested potential cognate receptor. We showed that proinflammatory and anti-inflammatory cytokines IFNγ, TNFα, and IL-10 did not induce expression of B7x on human or murine cancer cells. Following i.v. injection of CT26, a murine colon cancer cell line in the BALB/c background, we observed a significant increase in tumor burden in the lung of B7x-expressing CT26 mice compared to B7xnegative parental CT26 control mice. This was marked by a significant increase in M2 tumor associated macrophages and antigen-specific CD8 T cell exhaustion. Finally, we found through multiple systems that there was no evidence for B7x and Neuropilin-1 direct interaction. Thus, the B7x pathway has an essential role in modulating the innate and adaptive immune cell infiltrate in the tumor microenvironment with its currently unknown cognate receptor(s).

KW - B7x

KW - CD8 T cells

KW - Immune checkpoint

KW - Innate cells

KW - Pulmonary metastases

UR - http://www.scopus.com/inward/record.url?scp=85030867303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030867303&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21098

DO - 10.18632/oncotarget.21098

M3 - Article

AN - SCOPUS:85030867303

VL - 8

SP - 82740

EP - 82753

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 47

ER -